CA Patent

CA2641665A1 — Modified release formulation

Assigned to Boehringer Ingelheim International GmbH · Expires 2007-08-16 · 19y expired

What this patent protects

The invention is directed to the use of an extended release tablet formulation for pramipexole.

USPTO Abstract

The invention is directed to the use of an extended release tablet formulation for pramipexole.

Drugs covered by this patent

pramipexole-dihydrochloride (PRAMIPEXOLE DIHYDROCHLORIDE)

Patent Metadata

Patent number: CA2641665A1
Jurisdiction: CA
Classification: —
Expires: 2007-08-16
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.